CANY
PTCT icon

Caxton Associates (New York)’s PTC Therapeutics PTCT Stock Holding History

Caxton Associates (New York)’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,422
Closed -$212K – 551
2019
Q4 		$212K Buy
+4,422
New +$188K 0.03% 347

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Caxton Associates (New York)'s PTCT Position: Q1 2020 in Review

Caxton Associates (New York) sold out of PTC Therapeutics (PTCT) in Q1 2020, closing a stake of 4,422 shares — an estimated $212K sold.

Caxton Associates (New York) first reported a position in PTCT in Q4 2019 and held it in 1 quarter. The position peaked at $212K in Q4 2019. 203 funds tracked by Wall St. Rank hold PTCT as of Q1 2020.

  • Caxton Associates (New York) reported no remaining PTC Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 4,422 PTC Therapeutics shares in Q1 2020, an estimated $212K.
  • Caxton Associates (New York) first reported a position in PTC Therapeutics in Q4 2019 and held it in 1 quarter.
  • Caxton Associates (New York)'s PTC Therapeutics position peaked at $212K in Q4 2019.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2020.

Based on Caxton Associates (New York)'s 13F filing for Q1 2020, filed 15 May 2020.